The Oncology Institute, Inc. TOI IV drug inventory — Total Assets
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s iv drug inventory — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s IV drug inventory — total assets?
- The Oncology Institute, Inc. (TOI) reported IV drug inventory — total assets of $13.55M in Q1 2026.
- How has The Oncology Institute, Inc.'s IV drug inventory — total assets changed year-over-year?
- The Oncology Institute, Inc.'s IV drug inventory — total assets increased by 107.8% year-over-year, from $6.52M to $13.55M.
- What does IV drug inventory — total assets mean?
- This metric represents the ratio of intravenous drug inventory held for patient treatment relative to the company's total asset base. It measures the capital intensity and liquidity commitment tied up in specialized oncology pharmaceutical supplies. A higher ratio may indicate a significant investment in on-site drug availability to support infusion services, while also highlighting potential inventory management risks related to drug expiration or supply chain volatility.